IL-17A
50 programs · 47 companies
Programs
50
Companies
47
Active Trials
31
Targeting IL-17A
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | CMLPsA | |
| Tirasotorasib | Takeda | NDA/BLA | CML | |
| GIL-9779 | Gilead Sciences | Phase 1 | MDDRCC | |
| RVM-7089 | Revolution Medicines | Phase 3 | CLLMM | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | CML | |
| Polazanubrutinib | Tango Ther | Phase 1 | MCLFabry | |
| CSL-8235 | CSL Limited | Phase 1/2 | Atopic DermFL | |
| Zanuosocimab | Sun Pharma | Phase 3 | SLE | |
| Miritapinarof | Luye Pharma | Phase 2 | CholangiocarcinomaPancreatic Ca | |
| CHI-IIT-401 | Children's Oncology Grp | Phase 2/3 | T2D | |
| JOH-IIT-632 | Johns Hopkins | NDA/BLA | MCL | |
| Surazumab | Chinook (Novartis) | Phase 2/3 | PBCHS | |
| Capivorutinib | Chinook (Novartis) | Phase 2 | MSADHD | |
| Lisotapinarof | Gyre Ther | Approved | Crohn'sMelanoma | |
| Kemaosocimab | Onconova | Phase 3 | SchizophreniaMDS | |
| CTM-2131 | CytomX Therapeutics | Phase 3 | FL | |
| NBY-4130 | NovaBay Pharma | Phase 3 | OCDHeart Failure | |
| Adagrafotisoran | MiNT Therapeutics | Phase 2/3 | Hemophilia AMM | |
| Sovazumab | ObsEva (XOMA) | NDA/BLA | SLEBCC | |
| BIV-3779 | BioVie | Phase 2/3 | MGFSGS | |
| Rimaratamab | Rain (Qilu) | Phase 2 | IgAN | |
| Bemaosocimab | Laekna | Phase 3 | RettNarcolepsy | |
| Capiinavolisib | Alteogen | Phase 1/2 | ETHS | |
| NVE-9277 | Nvelop Ther | Phase 2 | SMAWet AMD | |
| EVO-4804 | Evommune | Approved | NB | |
| Lisozasiran | Fulcrum Ther | NDA/BLA | ADPKDMyelofibrosis | |
| Mavuzanubrutinib | MeiraGTx | Phase 1/2 | MCLCTCL | |
| Cevirasimod | Monte Rosa | Phase 2/3 | RA | |
| LPC-7933 | Lupin | Phase 3 | CeliacCSU | |
| 618-5050 | CanSino | Phase 2 | PsoriasisHemophilia A | |
| Sotozanubrutinib | Ocugen | Phase 1/2 | CTCLAsthma | |
| SPR-7869 | Sprint Bio | Phase 1 | PTSD | |
| Daranesiran | Sprint Bio | Preclinical | CholangiocarcinomaEoE | |
| Teranesiran | Clarity Pharma | Phase 2 | Wet AMD | |
| Talamavacamten | Adaptive Biotechnologies | Phase 1/2 | MyelofibrosisSchizophrenia | |
| SUP-4355 | Supernus Pharma | Phase 2 | MSRCC | |
| Bemazumab | Myovant Sciences | Phase 2/3 | RBMeso | |
| Zorirapivir | Orphazyme | NDA/BLA | NB | |
| MVI-2801 | Medivir | Preclinical | CKD | |
| Elracilimab | Mankind Pharma | NDA/BLA | GBM | |
| Ceviglumide | Zydus Lifesciences | Phase 3 | Urothelial CaPompe | |
| LAB-2279 | Genomma Lab | Phase 2 | DLBCL | |
| BIO-IIT-528 | Bio Farma | Phase 2 | Wet AMD | |
| PET-IIT-168 | Peter MacCallum | Preclinical | SLE | |
| WES-IIT-146 | West China Hosp | Phase 2/3 | Alzheimer's | |
| Lisomavacamten | 3SBio | NDA/BLA | CF | |
| Datorapivir | atai Life Sciences | Phase 2/3 | HS | |
| Miricilimab | Waters Corp | Phase 2/3 | ALL | |
| WAT-2618 | Waters Corp | Preclinical | MDSWM | |
| Fixatinib | Cipher Pharma | Phase 1/2 | OCDMigraine |